ID   HEC-108
AC   CVCL_2923
SY   HEC108
DR   CLO; CLO_0037286
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03470971
DR   BioSample; SAMN03472459
DR   BioSample; SAMN10987841
DR   cancercelllines; CVCL_2923
DR   Cell_Model_Passport; SIDM01608
DR   Cosmic; 1223494
DR   Cosmic; 1241342
DR   Cosmic; 1696755
DR   Cosmic; 2030466
DR   DepMap; ACH-000990
DR   GEO; GSM887067
DR   GEO; GSM888137
DR   IARC_TP53; 21065
DR   IARC_TP53; 30205
DR   JCRB; JCRB1123
DR   JCRB; NIHS0394
DR   LiGeA; CCLE_091
DR   PharmacoDB; HEC108_525_2019
DR   Progenetix; CVCL_2923
DR   Wikidata; Q54882254
RX   DOI=10.1007/978-4-431-53981-0_1;
RX   DOI=10.5795/jjscc.26.433;
RX   PubMed=2064198;
RX   PubMed=8847459;
RX   PubMed=12893190;
RX   PubMed=15053063;
RX   PubMed=22460905;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
WW   Info; MCLP; -; https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Japanese.
CC   Doubling time: 26.5 hours (Note=At 19th passage) (DOI=10.5795/jjscc.26.433); ~42 hours (Note=Lot 07072012) (JCRB=JCRB1123).
CC   HLA typing: A*24:20,26:01; B*40:01,52:01; C*12:02,15:02; DQA1*01:03,02:01; DQB1*03:02,03:02; DRB1*14:05,15:02 (PubMed=26589293).
CC   Microsatellite instability: Instable (MSI) (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; HGNC:11110; ARID1A; Simple; p.Arg1446Ter (c.4336C>T); Zygosity=Heterozygous (DepMap=ACH-000990).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Pro151His (c.452C>A); ClinVar=VCV000376639; Zygosity=Heterozygous (DepMap=ACH-000990).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Proteomics; Expression; Reverse-phase protein array.
CC   Omics: Proteomics; Quantitative.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; SNP array analysis.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=78.21%; East Asian, South=21.79%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Discontinued: JCRB; NIHS0394; true.
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
ST   Source(s): JCRB=JCRB1123; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 9,10,11,12,13 (PubMed=25877200)
ST   D13S317: 9,10,11,13,14 (JCRB=JCRB1123)
ST   D16S539: 11,12,13 (PubMed=25877200)
ST   D16S539: 12,13 (JCRB=JCRB1123)
ST   D18S51: 11,12,13
ST   D19S433: 11.2,12.2,14.2,15.2,16.2
ST   D21S11: 29,30,31
ST   D2S1338: 16,17,19,20
ST   D3S1358: 15,16,17
ST   D5S818: 6,12 (JCRB=JCRB1123)
ST   D5S818: 12 (PubMed=25877200)
ST   D7S820: 8,9,12
ST   D8S1179: 11,13
ST   FGA: 22,23
ST   Penta D: 8,9,10
ST   Penta E: 15,19,20
ST   TH01: 8,9
ST   TPOX: 11 (PubMed=25877200)
ST   TPOX: 11,12 (JCRB=JCRB1123)
ST   vWA: 15,16,17
DI   NCIt; C7359; Endometrial adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 31
//
RX   DOI=10.1007/978-4-431-53981-0_1;
RA   Kuramoto H., Hamano M., Imai M., Fujisawa T., Kamata Y., Arai T.,
RA   Kawaguchi M.;
RT   "HEC-1 cells: establishment of an in vitro experimental system in
RT   endometrial carcinoma.";
RL   (In book chapter) Cell and molecular biology of endometrial carcinoma; Kuramoto H., Nishida M. (eds.); pp.3-34; Springer; Tokyo; Japan (2003).
//
RX   DOI=10.5795/jjscc.26.433;
RA   Morisawa T.;
RT   "The results of primary culture of endometrial adenocarcinoma and
RT   characterization of its established cell line.";
RL   Nihon Rinsho Saibo Gakkai Zasshi 26:433-442(1987).
//
RX   PubMed=2064198; DOI=10.1111/j.1749-6632.1991.tb37884.x;
RA   Kuramoto H., Nishida M., Morisawa T., Hamano M., Hata H., Kato Y.,
RA   Ohno E., Iida T.;
RT   "Establishment and characterization of human endometrial cancer cell
RT   lines.";
RL   Ann. N. Y. Acad. Sci. 622:402-421(1991).
//
RX   PubMed=8847459;
RA   Okamura N., Mori Y., Endo T., Ito E., Kudo R.;
RT   "Experimental studies on the cell adhesion molecule E-cadherin and in
RT   vitro invasion of endometrial carcinoma cell lines.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 48:335-342(1996).
//
RX   PubMed=12893190; DOI=10.1016/S0090-8258(03)00335-4;
RA   Tanaka R., Saito T., Ashihara K., Nishimura M., Mizumoto H., Kudo R.;
RT   "Three-dimensional coculture of endometrial cancer cells and
RT   fibroblasts in human placenta derived collagen sponges and expression
RT   matrix metalloproteinases in these cells.";
RL   Gynecol. Oncol. 90:297-304(2003).
//
RX   PubMed=15053063;
RA   Kamata Y., Watanabe J., Hata H., Hamano M., Kuramoto H.;
RT   "Quantitative study on the correlation between p53 gene mutation and
RT   its expression in endometrial carcinoma cell lines.";
RL   Eur. J. Gynaecol. Oncol. 25:55-60(2004).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//